ecancermedicalscience

Special Issue

Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?

3 Dec 2020
Elham Sajjadi, Konstantinos Venetis, Cristian Scatena, Nicola Fusco

Precision immunotherapy is a crucial approach to improve the efficacy of anti-cancer treatments, particularly in the metastatic setting. In this respect, accurate patient selection takes advantage of the multidimensional integration of patients’ clinical information and tumour-specific biomarkers status. Among these biomarkers, programmed death-ligand 1, tumour-infiltrating lymphocytes, microsatellite instability, mismatch repair and tumour mutational burden have been widely investigated. However, novel tumour-specific biomarkers and testing methods will further improve patients’ outcomes. Here, we discuss the currently available strategies for the implementation of a precision immunotherapy approach in the clinical management of metastatic solid tumours and highlight future perspectives.

Related Articles

Afusat O Oduwoye, Elisha O Olabisi, Elizabeth F Ojo, Taiwo O Dosumu, Michael O Owoeye, Adelani Tijani, Deborah T Esan
Yanet Isabel Carrasco Rojas, Albert Gabriel Turpo Peqqueña, Natalia Camila Zenteno Tejada, Victoria Elena Quispe Pastor, Juan Augusto Martínez San Martín, Evelyn Maria Chambilla Huellcacure
Joaquin Fernandez-Alberti, Alex R Villaalta López, Guillermo Scolari, Alejandro Iotti, Marcelo Featherston
Bharath B Gangadharaiah, Ghazal Tansir, Sameer Rastogi, Simran Kaur, Vikas Garg, Ekta Dhamija, Adarsh Barwad, Shivanand Gamanagatti, Sandeep Bhoriwal, Maroof A Khan